Mineralys Therapeutics Inc (NASDAQ: MLYS) is a clinical-stage biopharmaceutical company developing lorundrostat, its lead product candidate, as a treatment for hypertension. The company generates no product revenue, operating entirely on capital raised through equity financing, including its initial public offering completed in February 2023. Mineralys holds approximately $10.0 million in product liability insurance coverage in the aggregate (as of the 10-K filed 2026-03-12), reflecting its pre-commercial status. The company is classified as an emerging growth company under the JOBS Act and has elected the extended transition period for accounting standards compliance. Jon Congleton, who joined as President and Chief Executive Officer in November 2020, leads the organization. The company's financials show an accumulated deficit on its balance sheets as of December 31, 2025 and December 31, 2024, consistent with a development-stage operation with no approved products and no commercial revenue as of the filing date.

Revenue model

No product revenue as of the 10-K filed 2026-03-12. Operations are funded through equity capital markets, including the February 2023 IPO. Revenue generation depends on future regulatory approval and commercialization of lorundrostat.

Products and services

Lorundrostat: lead product candidate in clinical development for hypertension, including a Phase 3 trial referenced as the Launch-HTN Phase 3 Trial (as referenced in the 10-K filed 2026-03-12). No approved or commercialized products as of the filing date.

Customers and end markets

Target end market is hypertension patients in the United States, with anticipated reliance on third-party payors including Medicare, Medicaid, commercial insurance, and managed healthcare organizations for future product reimbursement. No commercial customers as of the 10-K filed 2026-03-12.

Value-chain role

Clinical-stage drug developer. Conducts preclinical studies and clinical trials using third-party service providers. Has not yet reached manufacturing, marketing, or distribution stages for any approved product.

Geographic exposure

Primary operations in the United States. References to potential future operations in foreign jurisdictions including the European Economic Area in the context of data privacy compliance, but no disclosed international commercial presence as of the 10-K filed 2026-03-12.

Source: SEC 10-K, filed 2026-03-12

Industry: Pharmaceutical Preparations Peers: Aldeyra Therapeutics Inc Alector Inc Ambrx Biopharma Cayman, Inc. Arcutis Biotherapeutics Inc Disc Medicine Inc IGM Biosciences, Inc. Northwest Biotherapeutics Inc Seres Therapeutics Inc Zymeworks Inc